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ABSTRACT
Background
Current efforts to develop HIV vaccines that seek to stimulate immune responses have been
disappointing, underscoring the inability of natural immune responses to control HIV-1
infection. Here we tested an alternative strategy to induce anti-HIV immune responses by
inhibiting a host’s natural immune inhibitor.
Methods and Findings
We used small interfering RNA (siRNA) to inhibit suppressor of cytokine signaling (SOCS) 1, a
key negative regulator of the JAK/STAT pathway, and investigated the effect of this silencing on
the ability of dendritic cells (DCs) to induce anti-HIV-1 immunity. We found that SOCS1-silenced
DCs broadly induced enhanced HIV-1 envelope (Env)-specific CD8
þ cytotoxic T lymphocytes
and CD4
þ T helper cells, as well as antibody responses, in mice. Importantly, SOCS1-silenced
DCs were more resistant to HIV Env-mediated suppression and were capable of inducing
memory HIV Env-specific antibody and T cell responses. SOCS1-restricted signaling, as well as
production of proinflammatory cytokines such as interleukin-12 by DCs, play a critical role in
regulating the anti-HIV immune response. Furthermore, the potency of HIV DNA vaccination is
significantly enhanced by coimmunization with SOCS1 siRNA expressor DNA.
Conclusions
This study demonstrates that SOCS1 functions as an antigen presentation attenuator to
control both HIV-1-specific humoral and cellular responses. This study represents the first, to
our knowledge, attempt to elicit HIV-specific T cell and antibody responses by inhibiting a
host’s antigen presentation attenuator, which may open a new and alternative avenue to
develop effective therapeutic and prophylactic HIV vaccines.
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Despite extensive efforts, no effective human immunode-
ﬁciency virus (HIV) vaccine has emerged or is on the horizon
[1,2]. Increasing evidence indicates that the host’s natural
immunity has a major, albeit usually insufﬁcient, role in
limiting HIV-1 infection. CD8
þ cytotoxic T cells (CTLs) are
the main mediators of viral control, as demonstrated by the
dramatic increase in viremia in animal models after depletion
of CD8
þ T cells [3,4]. Although deﬁnitive evidence for a
protective role of antibodies is lacking, a number of
monoclonal antibodies generated from infected individuals
have broadly neutralizing activities against primary HIV-1
isolates [5]. Antibodies to the HIV-envelope (Env) protein,
gp120, protect animals such as monkeys and SCID-peripheral
blood lymphocyte mice from HIV or SIV infection [6,7]. Thus,
there is a growing consensus that an effective HIV immuni-
zation approach should be capable of inducing vigorous
protective CTL as well as antibody responses [5,8–11].
Dendritic cells (DCs), the most potent antigen-presenting
cells (APCs), mediate innate and adaptive immunity against
viral infection by providing proinﬂammatory cytokines and
by processing and presenting antigens to T cells [12]. DCs use
Toll-like receptors (TLRs) to recognize conserved microbial
structures such as lipopolysaccharide (LPS). TLR signaling
promotes DC maturation by activating mitogen-activated
protein kinase and nuclear factor-jB (NF-jB), which then
mediate the expression of various cytokines, resulting in the
induction of innate and adaptive immunity [13,14]. Hence,
exploiting the full immunostimulatory potential of DCs is
likely the key to achieving an effective immune response to
prevent or control HIV infection.
Suppressor of cytokine signaling (SOCS) 1 is a key negative
regulator of signaling of cytokines, such as interferon (IFN)-c,
interleukin (IL)-2, IL-6, IL-7, IL-12, and IL-15, through the
inhibition of the Janus kinases (JAKs) in many lineages of
immune cells [15,16]. Although the SOCS family includes
eight members, each member plays a unique role in
attenuating cellular signaling [15,16]. SOCS1 binds to the
JAK activation loop as a pseudosubstrate inhibitor through its
Src-homology 2 domain and targets JAK2 for degradation,
leading to the inhibition of the molecule, signal transducer
and activator of transcription (STAT) [15,16]. SOCS1-deﬁ-
cient (SOCS1
 / ) mice die neonatally, with severe systemic
inﬂammation and aberrant T cell activation, mainly as a
result of unbridled cytokine signaling [17–19]. Such SOCS1
 / 
mice are also hypersensitive to LPS, and SOCS1
 / DCs show a
more mature phenotype than do wild-type (WT) DCs and
induce autoreactive antibody production [20,21], suggesting
that SOCS1 plays a role in regulating DC functions by
inhibiting the JAK/STAT pathway and the TLR signaling
pathway directly or indirectly [15,22,23]. We have previously
shown that SOCS1 plays a critical role in regulating the
antigen presentation by DCs, and DCs in which SOCS1
expression is silenced by small interfering RNA (siRNA)
induce enhanced CTL responses against tumor-associated
antigens [24]. In agreement with this result, Hanada et al.
recently reported that immunization with SOCS1
 /  DCs
derived from SOCS1 genetic knockout mice induced a hyper
CD4
þ T helper cell (Th1)-type immune response and
antitumor activities [25].
Many attempts to develop HIV vaccines have sought to
stimulate immune responses by manipulating HIV antigens
and delivery systems and by using various adjuvants [5,8–10].
These efforts have been disappointing and have underscored
the inability of natural immune responses to control HIV-1
infection in most infected or immunized individuals. We
therefore tested an alternative hypothesis that anti-HIV
immune responses can be enhanced by silencing the host’s
natural immune inhibitors. In this study, we used siRNA to
silence SOCS1 and investigated the effect of this silencing on
the ability of DCs to induce anti-HIV-1 antibody and T cell
responses in mice.
Methods
Cytokine and Antibody ELISAs
Cytokine levels in cell culture supernatant were quantiﬁed
by ELISA analysis (BD Biosciences, San Diego, California,
United States), according to the manufacturer’s instructions.
To determine gp120-speciﬁc antibody and subclass titers, we
coated gp120 proteins (5 lg/ml in carbonate buffer [pH 9.6])
overnight at 4 8C, adding 12-fold serial dilutions of sera in
PBS-5% FBS to the wells for 1 h at room temperature. After
eight washes, biotinylated anti-mouse antibodies (anti-mouse
IgM, IgG, IgG1, IgG2a, IgG2b, or IgG3) were added to the wells
for 1 h at room temperature. Streptavidin-HRP was used as a
peroxidase substrate. The reaction was stopped by addition
of 50 llo f2MH 2SO4. Optical densities were read at 450 nm
on a BioAssay Reader (PerkinElmer, Wellesley, California,
United States). The results are expressed as reciprocal
endpoint titers, determined from a scatter plot with OD
values on the y-axis and dilution-1 on the x-axis, for which the
x-axis scale was logarithmic. After the data were plotted, a
logarithmic curve ﬁt was applied to each individual dilution
series, and the point where the curve ﬁt intersects the
positive-negative cutoff value was determined. The cutoff
value was calculated for each antibody isotype as the mean (6
3 standard deviations) of all dilutions from control mouse
sera. All samples tested in each experiment were assayed at
the same time.
Transduction of Bone Marrow-Derived DCs with Lentiviral
or Adenoviral Vectors
Recombinant lentiviral vectors, LV-SOCS1-siRNA and LV-
GFP-siRNA, were produced and titrated, as described
previously [24]. A recombinant adenoviral vector (Ad-IL-12)
expressing a biological active mouse IL-12 (a fusion protein
of p35 and p40) was purchased from InvivoGen (San Diego,
California, United States) and produced according to the
manufacturer’s instruction. Adenoviruses were titrated using
Adeno-X Rapid Titer Kits (BD Bioscience). Mouse bone
marrow (BM)-derived DCs were generated by culturing with
granulocyte-macrophage colony-stimulating factor (GM-CSF)
and IL-4, and transduced by lentiviral or adenoviral vectors as
described previously [24].
T Cell Enzyme-Linked Immunospot Assays
Enzyme-linked immunospot (ELISPOT) assays of isolated
CD4
þ or CD8
þ T cells were performed as described in our
previous reports [24]. Recombinant gp120 protein-pulsed
BM-DCs were used for T cell stimulation. An irrelevant
protein (ovalbumin [OVA]; Sigma, St. Louis, Missouri, United
States) was also used as a negative control. CD4
þ and CD8
þ T
cells were isolated from splenocytes with MACS CD4 (L3T4)
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California, United States).
B Cell Isolation and gp120 Antibody-Producing B Cell
ELISPOT Assay
Single-cell suspensions prepared from spleens in complete
RPMI 1640 medium were plated on plastic dishes for 1 h at 37
8Ci n5 %C O 2 to remove adherent macrophages. Non-
adherent cells were treated with anti-Thy1.2 and rabbit
complement for 45 min at 37 8C to lyse T cells. The purity of
the remaining B cells usually exceeded 90%. The B cell
ELISPOT assay was performed by a modiﬁed method
described before [26]. Brieﬂy, 96-well nitrocellulose-base
plates (Millipore Multiscreen PI, Billerica, Massachusetts,
United States) were coated overnight with gp120 in PBS.
The plates were washed six times with PBS and blocked with
RPMI 1640 containing 10% FBS at 37 8C for 2 h. The isolated
B cells were seeded into wells (5 3 10
5 cells/well) and
incubated for 20 h at 37 8Ci n5 %C O 2. The cells were then
removed by six washes with PBS containing 0.5% Tween 20
(Sigma). Biotinylated anti-mouse IgG (BD Pharmingen, San
Diego, California, United States), diluted in PBS containing
0.5% FBS to 1 lg/ml, was added, and the mixture incubated at
37 8C for 2 h. The avidin:biotinylated enzyme complex ([ABC];
Vector Laboratories, Burlingame, California, United States)
was added for an additional hour. Anti-gp120 IgG was
detected after a 4-min reaction with AEC (3-amino-9-ethyl-
carbazole; Sigma). The results were evaluated by ZellNet
Consulting (New York, New York, United States) with an
automated ELISPOT reader system (Carl Zeiss, Thornwood,
New York, United States), using KS ELISPOT 4.3 software.
Quantitative Real-Time PCR Analysis of BAFF and APRIL
The relative expression of SOCS1 in transfected mouse
BM-DCs was evaluated by quantitative real-time PCR. Total
RNA was extracted from DCs, using Trizol reagent (Invitro-
gen, Carlsbad, California, United States), and 1.0 lg of total
RNA for each sample was reverse transcribed with random
hexamer primers and SuperScript First-Strand Synthesis kits
(Invitrogen). Real-time 59-nuclease ﬂuorogenic PCR analysis
was performed on an ABI 7900HT Sequence Detection
System (Applied Biosystems, Foster City, California, United
States) in 20-ll quadruplicate reactions with the equivalent of
5 ng of starting RNA material per reaction as template. The
following primers were used for BAFF and APRIL: BAFF
sense, 59-TGCTATGGGTCATGTCATCCA-39 and anti-sense,
59-GGCAGTGTTTTGGGCATATTC-39; APRIL sense, 59-
TCACAATGGGTCAGGTGGTATC-39 and anti-sense, 59-
TGTAAATGAAAGACACCTGCACTGT-39. TaqMan probe,
forward and reverse primer for 18S were obtained from
TaqMan Rodent 18S control reagents (Applied Biosystems).
The PCR parameters were these recommended for the
TaqMan Universal PCR Master Mix kit (Applied Biosystems),
with BAFF, APRIL, and 18S reactions performed in separate
tubes. BAFF and APRIL levels were normalized to 18S rRNA,
while BAFF or APRIL expression (relative to the control value
of mock-transfected, stimulated DCs) was calculated by the
Comparative Ct method [24,27].
CTL Assays
CD8
þ CTL responses were assessed with a standard
chromium release assay [24] that measures the ability of in
vitro-restimulated splenocytes to lyse target cells. Splenocytes
pooled from immunized mice were restimulated in vitro in
RPMI-1640 containing gp120 proteins (20 lg/ml) for 4–6 d.
Target cells pulsed with 20 lg/ml of gp120 protein overnight
were labeled with
51Cr-sodium chromate solution for 90 min.
Different numbers of effector cells were incubated with a
constant number of target cells (1 3 10
4/well) in 96-well V-
bottom plates (200 ll/well) for 3 h at 37 8C. The supernatants
(100 ll) from triplicate cultures were collected. Percent cell
lysis was calculated as (experimental release – spontaneous
release)/(maximum release – spontaneous release) 3 100.
T and B Cell Proliferation Assay
CD4
þ or CD8
þ T cells (1310
6 per well) and B cells (1310
5
per well) isolated as described above were cultured in
complete medium in triplicate wells of 96-well plates with
or without various stimuli. On the fourth day of culture, wells
were pulsed with 1 lCi of [
3H]-thymidine for 16 h. Plates were
then harvested, and incorporated [
3H]-thymidine was meas-
ured using a MicroBeta scintillation counter (TopCount
NXT, Packard, Meriden, Connecticut, United States).
DC Immunization
The recombinant soluble gp120 (SF162) protein, with a
purity of over 95% and mostly in a monomeric form, was
produced and puriﬁed from CHO cells and kindly provided
by the National Institutes of Health AIDS Research and
Reference Program and Chiron Corporation. On day 5 of BM
culture, DCs derived from BM of WT mice or IL-12 receptor
knockout (KO) mice were transduced with LV-SOCS1-siRNA
or LV-GFP-siRNA at a multiplicity of infection (MOI) of 5
[24], and pulsed with proteins for 2 h. The transduced DCs
were then stimulated with LPS (100 ng/ml, Sigma) or tumor
necrosis factor a (TNFa) (50 ng/ml, Peprotech, Rocky Hill,
New Jersey, United States) ex vivo for 24 h, washed with PBS,
and injected into mice (Jackson Laboratory, Bar Harbor,
Maine, United States) via a foot pad. IL-12 receptor KO mice
(B6.129S1-Il12rb1
tm1Jm) in a C57BL/6 background were pur-
chased from the Jackson Laboratory. The immunized mice
were treated with LPS, PolyI:C, or R837 (30 lg/mouse) or
murine IL-12 (1 lg/mouse) intraperitoneally three times on
days 1, 3, and 5 after each DC immunization.
DNA Vaccination
The pSuper-SOCS1-siRNA expression vector was gener-
ated as described previously [24]. An HIV Env gp140
expression vector (pCMV/R-gp140CF) in which the gp120/
Figure 1. Enhanced gp120-Specific Antibody and T Cell Responses Induced by SOCS1-Silenced DCs
Groups of C57BL/6 mice were immunized with gp120 (SF162) protein-pulsed, transduced BM-derived DCs (1 3 10
6 cells/mouse) twice at a weekly
interval, followed by PolyI:C or R837 stimulation (30 lg/mouse) in vivo three times on days 1, 3, and 5 after each DC immunization, and sera and
splenocytes were collected from each group of mice 14 d later. HIV gp120-specific IgG subclass titers (A) from the pooled sera of each group (4–6 mice/
group) were quantified by capture ELISA. CD8
þ T cells (B) and CD4
þ T cells (C) isolated from pooled splenocytes were used for IFN-c ELISPOT assays
stimulated with gp120 proteins. Intracellular IFN-c staining of CD8
þ T cells from the pooled splenocytes were also performed (D). Representative data
from one of three experiments are presented. NS, no stimulation. *P , 0.01, LV-SOCS1-siRNA-DCs versus LV-GFP-siRNA-DCs.
DOI: 10.1371/journal.pmed.0030011.g001
PLoS Medicine | www.plosmedicine.org January 2006 | Volume 3 | Issue 1 | e11 0078
HIV Vaccine/Immune Inhibitor SilencingPLoS Medicine | www.plosmedicine.org January 2006 | Volume 3 | Issue 1 | e11 0079
HIV Vaccine/Immune Inhibitor Silencinggp41 cleavage site and fusion domain of HIV gp160 (codon
usage-optimized HIV-1 strain JRFL) was deleted and the
gp140CF gene was placed under control of the CMV
promoter, was constructed. Endotoxin-free DNA was pre-
pared with a DNA isolation kit from Qiagen (Valencia,
California, United States), resuspended in endotoxin-free
PBS (Sigma-Aldrich) at a ﬁnal concentration of 1 lg/ll, and
stored at  20 8C until used for injection. On the scheduled
day of vaccination, 50 lgo fgp140CF DNA or 200 lg of the
mixture of gp140CF DNA (50 lg) and pSuper-SOCS1-siRNA
expressor DNA (150 lg) [24] was injected into the quadriceps
of each mouse [28,29]. The immunized mice were then
treated with PolyI:C or R837 (30 lg/mouse) intraperitoneally
three times on days 1, 3, and 5 after each DNA immunization
[24].
Statistical Analysis
We used the Student’s t-test, and 95% conﬁdence limits, to
assess results for statistical signiﬁcance, deﬁned as P , 0.05.
Results are typically presented as means 6 standard error.
Results
Silencing of SOCS1 in DCs Enhances the HIV Env-Specific
Antibody Response
We ﬁrst investigated the effect of SOCS1 silencing on the
ability of DCs to induce anti-HIV antibody responses. We
used HIV Env for this study, since it can induce both cellular
and neutralizing antibody responses. A recombinant lenti-
viral vector (LV-SOCS1-siRNA) that expresses SOCS1 siRNA
and has the ability to down-regulate about 90% of SOCS1
mRNA in transfected cells and a control vector (LV-GFP-
siRNA) were generated, as described previously [24]. Mouse
BM-derived DCs were transduced with LV-SOCS1-siRNA or
LV-GFP-siRNA, loaded with recombinant HIV gp120 pro-
teins, and matured with TNFa ex vivo. Groups of mice were
then immunized with the transduced DCs twice at a weekly
interval. LV-SOCS1-siRNA-DCs elicited greater gp120-spe-
ciﬁc IgG responses than did the control LV-GFP-siRNA-DCs
(Figure S1A and S1B). We further tested whether in vivo
stimulation with a TLR agonist, PolyI:C or R837, could
further enhance anti-gp120 immune responses, since SOCS1
is an inducible feedback inhibitor [15,16] and immune
responses against tumor-associated antigens induced by
SOCS1-silenced DCs were preferentially enhanced by in vivo
stimulation with LPS in our previous study [24]. Groups of
mice were then immunized with the transduced DCs twice at
a weekly interval, followed by stimulation with a low dose of
PolyI:C or R837 in vivo after each DC immunization. Figure 1
shows increases in HIV Env-speciﬁc antibody titers in all IgG
subclasses in mice immunized with LV-SOCS1-siRNA-DCs,
compared with the corresponding IgG subclasses in LV-GFP-
siRNA-DC mice. In vivo stimulation with PolyI:C or R837
preferentially enhanced HIV Env-speciﬁc antibodies, espe-
cially IgG2 and IgG3, in mice immunized with LV-SOCS1-
siRNA-DCs (Figure 1). The Env-speciﬁc antibody subclass
proﬁle showed a Th1-polarized IgG response, higher IgG2a (a
subclass associated with a Th1 response [30]), induced by LV-
SOCS1-siRNA-DCs. Similar results were obtained in repeated
experiments. In addition, in vivo stimulation with LPS also
signiﬁcantly enhanced HIV Env-speciﬁc antibody titers in
LV-SOCS1-siRNA-DC mice (Figure S2). We did not perform
neutralizing assays, since mice are not an appropriate species
for reliable testing of HIV neutralizing activities [5]. We
further found that SOCS1 silencing enhanced antibody
responses to other strains of HIV Env proteins and antigens
such as OVA (unpublished data). These results demonstrate
that HIV Env-speciﬁc antibody responses are enhanced by
the silencing of SOCS1 in DCs, implying a critical role for
SOCS1 in DCs in controlling antigen-speciﬁc antibody
responses.
Silencing of SOCS1 in DCs Enhances HIV gp120-Specific T
Cell Responses
We next asked whether SOCS1 silencing could enhance
HIV Env-speciﬁc CTL responses by using IFN-c ELISPOT,
intracellular cytokine staining, and CTL assays to test the
functional status of CD8
þT cells in the immunized mice. CTL
activities against gp120-pulsed target cells in the LV-SOCS1-
siRNA-DC mice were more potent than those in the LV-GFP-
siRNA-DC mice (see Figure S1). The CTL activity detected in
these assays was gp120-speciﬁc, since splenocytes from LV-
SOCS1-siRNA-DC mice lacked any apparent CTL activity
against non-gp120-pulsed target cells (unpublished data).
Natural killer cell (NK) activities were also enhanced in mice
immunized with SOCS1-silenced DCs (Figure S3). In vivo
stimulation with PolyI:C or R837 further enhanced the CD8
þ
T cell responses in LV-SOCS1-siRNA-DC-immunized mice
(Figure 1). Intracellular staining of splenocytes with IFN-c
also showed higher percentages of IFN-c
þ CD8
þ T cells in LV-
SOCS-siRNA-DC mice (Figure 1). Various TLR agonists had a
comparable ability to enhance the immunostimulatory
potency of LV-SOCS1-siRNA-DCs (Figure S4). In addition,
the percentage of perforin-positive CD8
þ Tc e l l sw a s
signiﬁcantly increased in mice immunized with gp120-pulsed
LV-SOCS1-siRNA-DCs (Figure S5), suggesting that SOCS1-
silenced DCs may qualitatively enhance CTL responses as
well. LV-SOCS1-siRNA-DC immunization induced enhanced
HIV gp120-speciﬁc CD4
þ T cells (Figure 1). We compared the
potency of SOCS1-silenced DC immunization and protein
adjuvant immunization. Figure 2A–2C show that gp120-
pulsed SOCS1-silenced DCs induced potent CD8
þ and CD4
þ
T cell responses as well as antibody responses, especially
IgG2a, IgG2b, and IgG3. In contrast, immunization with the
same amount of recombinant gp120 proteins formulated in
incomplete Freund’s adjuvant (IFA) only induced weaker
antibody responses and barely detectable CD8
þ and CD4
þ T
cell responses. Taken together, these results demonstrate a
balanced and enhanced antibody and T cell response against
HIV Env in mice immunized with SOCS1-silenced DCs,
especially when stimulated in vivo with a low dose of TLR
agonists, suggesting that SOCS1 in DCs critically regulates
both anti-HIV humoral and cellular immunity.
Enhanced gp120-Specific Th Response Induced by SOCS1-
Silenced DCs
Given the role of cytokines in programming Th1 versus
Th2 responses [31,32], we reasoned that SOCS1 silencing
might affect CTL and antibody responses by regulating the
production of cytokines by DCs. Figure 3A and 3B shows
signiﬁcantly increased levels of IL-12 (p70), IFN-c, and TNFa,
which promote Th1-polarized responses, produced by LV-
SOCS1-siRNA-BM-DCs generated in the culture containing
GM-CSF and IL-4, compared with GFP-siRNA-DCs generated
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LPS with anti-CD40 antibodies. The expression of EOMES
mRNA, a transcription factor involved in the regulation of
IFN-c, was enhanced in LV-SOCS1-siRNA-DCs compared
with LV-GFP-siRNA-DCs after stimulation with LPS (Figure
S6), in agreement with a recent report by Hanada et al [25]. In
addition, signiﬁcant increases of IL-4, IL-6, and IL-10, which
promote Th2-polarized responses, were also seen in the
SOCS1-silenced BM-DCs (P , 0.01). Interestingly, we found
that both LV-SOCS1-siRNA-DCs and LV-GFP-siRNA-DCs
generated in a culture containing GM-CSF alone only
produced low levels of IL-12 (p70), even when stimulated
with LPS and anti-CD40 antibodies. These results suggest that
IL-4 is a potent enhancer of IL-12 production, which is
supported by an earlier ﬁnding [33]. Collectively, these data
suggest that the higher levels of both Th1- and Th2-
promoting cytokines produced by SOCS1-silenced DCs may
account for the enhanced ability of SOCS1-silenced DCs to
induce both HIV Env-speciﬁc CTL and antibody responses.
SOCS1 silencing in DCs clearly promoted antibody and
CTL responses, but it was unclear whether HIV Env-speciﬁc
CD4
þ Th responses, which are intimately involved in the
induction of antibody and CTL responses, are also enhanced
by SOCS1 silencing. We therefore isolated CD4
þ T cells from
immunized mice using CD4
þ microbeads and analyzed them
with various assays. As depicted in Figure 3C, the frequencies
of gp120-speciﬁc CD4
þT cells were signiﬁcantly higher in LV-
SOCS1-siRNA-DC mice than in LV-GFP-siRNA-DC mice.
3H-
thymidine incorporation assays showed that the CD4
þ T cells
from LV-SOCS1-siRNA-DC mice proliferated more actively
than those from LV-GFP-siRNA-DC mice in response to
stimulation with gp120-pulsed DCs (Figure 3D). Analysis of
the cytokine proﬁles produced by CD4
þ T cells isolated from
LV-SOCS1-siRNA-DC mice after stimulation with gp120-
pulsed DCs revealed increased levels of both Th1-polarizing
(IFN-c, IL-12, and TNFa) and Th2-polarizing (IL-4 and IL-10)
cytokines (Figure 3E). These results indicate that SOCS1-
silenced DCs induce an enhanced Th1-polarized, but a mixed
Th1 and Th2, response against HIV Env, which is consistent
with the Th1-polarized gp120-speciﬁc IgG subclass proﬁle
(higher IgG2a) shown in Figures 1B and 2B.
Figure 2. Comparison of gp120-Specific Antibody and T Cell Responses Induced by Protein Immunization and SOCS1-Silenced DCs
Groups of C57BL/6 mice were immunized with gp120 protein (20 lg/ml)-pulsed, transduced BM-derived DCs (1310
6 cells/mouse) or the same amount
of gp120 protein formulated in IFA (20 lg/mouse) twice at a weekly interval. All of the mice were injected with PolyI:C or R837 (30 lg/mouse) in vivo
three times on days 1, 3, and 5 after each immunization, and sera and splenocytes were collected from each group of mice 14 d later. HIV gp120-specific
IgG subclass titers (A) from the pooled sera of each group (4–6 mice/group) were quantified by capture ELISA. CD8
þ T cells (B) and CD4
þ T cells (C)
isolated from pooled splenocytes were used for IFN-c ELISPOT assays stimulated with gp120 proteins. Representative data from one of three
experiments are presented. *P , 0.01, gp120 protein þ IFA versus gp120-pulsed LV-SOCS1-siRNA-DCs.
DOI: 10.1371/journal.pmed.0030011.g002
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HIV Vaccine/Immune Inhibitor SilencingFigure 3. Enhanced Production of Both Th1- and Th2-Polarizing Cytokines by SOCS1-Silenced DCs and Activated CD4
þ Th
(A) Enhanced production of both Th1- and Th2-polarizing cytokines by SOCS1-silenced DCs. BM-DCs transfected with SOCS1 siRNA or control [24] were
stimulated with LPS (100 ng/ml). Concentrations of various cytokines in the culture media were analyzed by ELISA 24 h after stimulation. NS, no
stimulation. *P , 0.01, LV-SOCS1-siRNA-DCs versus LV-GFP-siRNA-DCs.
(B) IL-12 production by transduced DCs. BM cells were cultured with mGM-CSF (20 lg/ml only or mGM-CSF and mIL-4 (20 lg/ml) [24] for 6 d and then
transduced with LV-SOCS1-siRNA or LV-GFP-siRNA. The transduced DCs (5310
5/ml) were then stimulated with LPS (100 ng/ml) and plate-coated anti-
CD40 mAb (5 lg/ml, BD Bioscience) in the presence or absence of IL-4. Concentrations of IL-12 (p70) in the culture media were analyzed by ELISA 24 h
after stimulation and are presented from one of three independent experiments. *P , 0.01, LV-SOCS1-siRNA (GM-CSFþIL-4) versus LV-GFP-siRNA (GM-
CSF þ IL-4).
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Silenced DCs
DCs have been shown to directly trigger B cell prolifer-
ation, maturation, and class-switch recombination by pro-
ducing APRIL (a proliferation-inducing ligand) and BAFF (B-
cell activating factor of the TNF family, also known as BLyS),
members of the TNF superfamily [34–36]. We examined the
effect of SOCS1 silencing on the production of APRIL and
BAFF by DCs using real-time RT-PCR. LV-SOCS1-siRNA-DCs
expressed higher levels of APRIL and BAFF mRNA upon LPS
stimulation than did LV-GFP-siRNA-DCs (Figure 4A), in
agreement with the increased expression of BAFF and APRIL
in SOCS1
 /  DCs [20].
To test the ability of SOCS1-silenced DCs to enhance
activation of gp120-speciﬁc B cells, we used an anti-gp120
IgG-speciﬁc B cell ELISPOT assay to directly examine the
frequencies of anti-gp120 IgG-producing B cells in the
immunized mice. Frequencies of anti-gp120 IgG-producing
B cells were signiﬁcantly higher in LV-SOCS1-siRNA-DC
mice than in LV-GFP-siRNA-DC mice (P , 0.01) (Figure 4B).
Higher percentages of B cells exhibited an activated
phenotype characterized by high levels of CD69, CD40, and
CD86 in LV-SOCS1-siRNA-DC mice, compared with B cells
from LV-GFP-siRNA-DC mice (unpublished data). We further
puriﬁed B cells from the spleens of immunized mice and
stimulated them with various stimuli. Figure 4C shows that B
cells from LV-SOCS1-siRNA-DC mice proliferated more
vigorously when costimulated with anti-CD40 and IL-4 than
did B cells from LV-GFP-siRNA-DC mice. Interestingly, B
cells from LV-SOCS1-siRNA-DC mice, but not those from
LV-GFP-siRNA-DC mice, responded strongly to IL-4 or anti-
CD40 only, suggesting that increased numbers of B cells were
already activated in vivo by immunization with LV-SOCS1-
siRNA-DCs. We also found that B cells from LV-SOCS1-
siRNA-DCs mice produced higher levels of various cytokines,
including IL-6, IL-2, and TNF-a, in response to various
stimuli (Figure 4D). The enhanced B cell activation and
antibody production induced by SOCS1-silenced DCs were
likely CD4
þ T cell-dependent, since the antibody production
was compromised in CD4 knockout mice immunized with
SOCS1-silenced DCs (unpublished data). Collectively, these
results suggest that SOCS1-silenced DCs produce enhanced
levels of B lymphocyte stimulators (BAFF and APRIL) and
Th2-polarizing cytokines, leading to more effective activation
of HIV Env-speciﬁc B cells and Th cells.
Long-Term HIV Env-Specific CTL and Antibody Responses
Induced by SOCS1-Silenced DCs
Having shown that SOCS1 silencing in DCs enhances the
primary HIV Env-speciﬁc CTL and antibody responses, we
tested whether SOCS1-silenced DCs would induce memory
HIV-speciﬁc CTL and antibody responses. Figure 5A shows
that mice immunized with LV-GFP-siRNA-DCs had very low
levels of gp120-speciﬁc antibodies at 6 mo after immuniza-
tion, while LV-SOCS1-siRNA-DC mice still retained signiﬁ-
cant titers of gp120-speciﬁc IgG1 and IgG2 antibodies in their
sera. At 1 wk after booster immunization, the LV-SOCS1-
siRNA-DC mice showed strong recall antibody responses,
with a mean titer of anti-gp120 IgG1 at 2 3 10
5 and anti-
gp120 IgG2 at 1 3 10
5, while the LV-GFP-siRNA-DC mice
showed poor recall antibody responses, with a mean titer of
IgG1 at 3 3 10
3 and IgG2 at 4 3 10
2. These data show that
SOCS1-silenced DCs exhibit about 64- and 255-fold increases
in the titers of IgG1 and IgG2a antibodies, respectively,
compared to LV-GFP-siRNA-DCs.
The maintenance of memory HIV-speciﬁc CTLs and Th
was assessed by examining gp120-speciﬁc CD8
þ and CD4
þ T
cell responses with IFN-c ELISPOT assays. Figure 5B shows
that strong gp120-speciﬁc CTL responses were detected in
LV-SOCS1-siRNA-DC mice, but not in LV-GFP-siRNA-DC
mice, at 6 mo after immunization (249 IFN-c spots per 5310
5
CD8
þT cells in LV-SOCS1-siRNA-DC mice versus three IFN-c
spots in LV-GFP-siRNA-DC mice). Vigorous gp120-speciﬁc
CTL responses were rapidly induced by booster immuniza-
tion in LV-SOCS1-siRNA-DC mice, but not in LV-GFP-
siRNA-DC mice (446 IFN-c spots per 5 3 10
5 CD8
þ T cells in
LV-SOCS1-siRNA-DC mice versus 16 IFN-c spots in LV-GFP-
siRNA-DC mice on day 7 post-boosting) (Figure 5B).
Costaining of intracellular IFN-c and the surface CD44
memory marker of CD8
þ T cells also showed a higher
percentage of CD44hi and IFN-c
þ CD8
þ T cells in LV-
SOCS1-siRNA-DC mice, compared with LV-GFP siRNA-DC
mice at 6 mo post-immunization (Figure 5C). Similarly,
gp120-speciﬁc CD4
þ Th responses were maintained and
rapidly induced in LV-SOCS1-siRNA-DCs mice at 6 mo after
immunization (391 IFN-c spots per 5 3 10
5 CD4
þ T-cells in
LV-SOCS1-siRNA-DC mice versus 37 IFN-c spots in LV-GFP-
siRNA-DC mice on day 7 post-boosting) (Figure 5D). Thus,
immunization with SOCS1-silenced DCs effectively induces
long-term HIV Env-speciﬁc CTL, Th, and antibody responses.
No apparent toxicity was observed in the mice immunized
with LV-SOCS1-siRNA-DCs pulsed with gp120 up to 7 mo
after immunization. Histological analysis of all major organs
and tissues of the immunized mice revealed no pathologic
inﬂammation (unpublished data). Levels of IgG and anti-
dsDNA were comparable in LV-SOCS1-siRNA-DC and mock
DC mice. These data suggest that gp120-pulsed LV-SOCS1-
siRNA-DC immunization does not cause pathological inﬂam-
mation in mice.
Resistance of SOCS1-Silenced DCs to HIV Env-Mediated
Immune Suppression
The HIV Env protein gp120 can suppress the ability of DCs
to produce proinﬂammatory cytokines and to stimulate T
cells [37–40]. We therefore asked whether the enhanced
activation of DCs by SOCS1 silencing might overcome the
inhibitory effects of gp120 proteins on the cytokine produc-
tion and immunostimulatory capacity of DCs. IL-12 was
selected as a representative cytokine for these experiments,
because DC-derived IL-12 was found to play a dual role,
driving Th1 development as well as directly signaling B cells
(C–E) CD4
þ Th responses induced by LV-SOCS1-siRNA-DCs. CD4
þ T cells were isolated from pooled splenocytes of different groups of mice and
subjected to the following assays. Numbers of IFN-c-producing CD4
þ T cell precursors were determined with the ELISPOT assay (C).
3H-thymidine
incorporation rates of the isolated CD4
þ T cells were determined on the fourth day of restimulation with gp120-pulsed DCs (D). Cytokine levels in the
culture medium of isolated CD4
þ cells stimulated with gp120-pulsed DCs for 48 h were determined by ELISA (E). The mean results (þ standard error)
from one of three experiments are presented. *P , 0.01, LV-SOCS1-siRNA-DC versus LV-GFP-siRNA-DC mice.
DOI: 10.1371/journal.pmed.0030011.g003
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6A, LV-SOCS1-siRNA-DCs in the presence of gp120 proteins
retained the ability to respond to LPS. In contrast, the
response of LV-GFP-siRNA-DCs to LPS stimulation was
severely compromised by the presence of gp120 proteins.
The susceptibility of SOCS1-silenced DCs to gp120-mediated
suppression was further investigated in vivo. Mice were
immunized with OVA-pulsed transduced DCs with or without
pretreatment of gp120 proteins ex vivo. Pre-exposure to
gp120 proteins did not have apparent effects on the ability of
LV-SOCS1-siRNA-DCs to induce OVA-speciﬁc antibody
responses (Figure 6B and 6C), nor did it compromise OVA-
speciﬁc CD8
þ CTL and CD4
þ Th responses induced by LV-
SOCS1-siRNA-DCs (P . 0.05) (Figure 6D and 6E). However,
such pretreatment signiﬁcantly reduced the ability of LV-
GFP-siRNA-DCs to induce OVA-speciﬁc antibody and CTL
responses (P , 0.05) (Figure 6B–6E). These results indicate
that SOCS1 silencing renders DCs resistant to HIV gp120-
mediated suppression, probably because of the enhanced
cytokine production and hyperactivated state of SOCS1-
silenced DCs [20,24].
Regulation of gp120-Specific Cellular Responses by
SOCS1-Restricted IL-12 Signaling in DCs
S i n c eI L - 1 2i sap o t e n ts t i m u l a t o ro fT h 1i m m u n e
responses [44] and is regulated by SOCS1 [45], we further
tested whether in vivo stimulation with IL-12, which may be
applicable in the clinic, is also effective in enhancing the
potency of LV-SOCS1-siRNA-DCs. HIV gp120-pulsed, trans-
duced DCs that were matured ex vivo with TNFa were
transferred into mice. The recipient mice were then
stimulated in vivo three times with a low dose of recombinant
mouse IL-12 (1 lg/mouse/injection). Figure 7A shows that
gp120-speciﬁc CD8
þ CTL activities in LV-SOCS1-siRNA-DC-
immunized mice were signiﬁcantly enhanced by in vivo IL-12
stimulation, as demonstrated by IFN-c ELISPOT assay. In
contrast, in vivo administration with IL-12 only had a modest
effect on CTL activities in LV-GFP-siRNA-DC-immunized
mice. Figure 7B also shows that in vivo IL-12 stimulation
preferentially enhanced gp120-speciﬁc CD4
þ Th responses
induced by LV-SOCS1-siRNA-DCs. These results suggest that
in vivo administration with a representative proinﬂammatory
cytokine (IL-12) preferentially enhances the immunostimula-
tory ability of SOCS1-silenced DCs.
The preferential enhancement of the immunostimulatory
ability of SOCS1-silenced DCs by a low dose of IL-12 in vivo
suggests that SOCS1-restricted cytokine signaling in antigen-
presenting DCs is critical in regulating antigen presentation
and anti-HIV immunity. To further investigate this possibil-
ity, we compared the immunostimulatory ability of DCs
transfected with a recombinant adenovirus expressing mouse
IL-12 cytokine (Ad-IL-12) or with LV-SOCS1-siRNA. Mice
were immunized with gp120-pulsed DCs transfected with
various MOIs of Ad-IL-12 (10 to 1,000), DCs transfected with
LV-SOCS1-siRNA (MOI of 5), or DCs cotransfected with LV-
SOCS1-siRNA (MOI of 5) and Ad-IL-12 (MOI of 10). DCs
transfected with Ad-IL-12 at a MOI of 300 constitutively
produced a high level of IL-12, comparable to that produced
by LV-SOCS1-siRNA-DCs after stimulation with LPS (un-
published data). Figure 7C and 7D show that gp120-speciﬁc
CTL and Th responses were enhanced in mice immunized
with DCs transfected with Ad-IL-12 (MOIs of 10 to 1,000),
when compared with control LV-GFP-siRNA-DC. Interest-
ingly, DCs transfected with either low or high MOIs of Ad-IL-
12 induced comparable levels of gp120-speciﬁc CD8
þ and
CD4
þ T cell responses (Figure 7C and 7D), suggesting that
gp120-speciﬁc immune responses cannot be simply boosted
by administration of increasing doses of proinﬂammatory
cytokines. However, SOCS1-silenced DCs cotransfected with
a low MOI (10) of Ad-IL-12 induced signiﬁcantly more potent
gp120-speciﬁc CD8
þ CTL and CD4
þ Th responses than
SOCS1-silenced DCs or WT DCs transfected with either low
or high MOIs (10 to 1,000) of Ad-IL-12 (Figure 7C and 7D),
supporting a critical role of SOCS1-restricted IL-12 signaling
in DCs for the induction of anti-HIV cellular responses. To
further determine the role of autocrine signaling of IL-12 in
antigen-presenting DCs, we compared the CTL and Th
responses induced by DCs derived from IL-12 receptor KO
mice or WT mice. These DCs were cotransfected with LV-
SOCS1-sRNA and Ad-IL-12 and then injected into WT mice.
Ad-IL-12/SOCS1-siRNA-DCs derived from IL-12 receptor KO
mice exhibited a signiﬁcantly reduced ability to induce
gp120-speciﬁc CTL responses, compared with Ad-IL-12/
SOCS1-siRNA DCs from WT mice (Figure 7C and 7D).
Similarly, in vivo stimulation with IL-12 showed a signiﬁ-
cantly reduced ability to induce gp120-speciﬁc CTL and Th
responses induced by IL-12R KO LV-SOCS1-siRNA-DCs,
compared with WT LV-SOCS1-siRNA-DCs (Figure 7A and
7B). Taken together, these results indicate that SOCS1-
restricted, autocrine signaling of proinﬂammatory cytokines
such as IL-12 in DCs, in addition to the SOCS1-restricted
production of proinﬂammatory cytokines by DCs, plays a
critical role in controlling anti-HIV immune responses.
Potency of HIV DNA Vaccine Enhanced by
Coimmunization with SOCS1-siRNA DNA
The ability of SOCS1-silenced DCs to enhance both HIV
Env-speciﬁc CTL and antibody responses suggests that our
SOCS1 silencing approach might be useful in improving the
potency of HIV DNA vaccination. We generated a HIV
gp140CF expression vector, in which the gp120/gp41 cleavage
site and fusion domain of gp160 were deleted and the
gp140CF gene was placed under control of the CMV
promoter. To test the effect of SOCS1 siRNA on DNA
vaccination, we injected mice with gp140CF DNA only or with
am i x t u r eo fgp140CF DNA and pSuper-SOCS1-siRNA
expressor DNA, which was constructed previously [24], weekly
for 3 wk, followed by PolyI:C or R837 stimulation (30 lg/
mouse) in vivo after each DNA immunization. Enhanced HIV
Env-speciﬁc antibody titers were evident in mice coimmu-
nized with pSuper-SOCS1-siRNA DNA (Figure 8). gp120-
speciﬁc IgG2a antibodies, indicative of a Th1-polarized
immune response [46], were preferentially enhanced, indicat-
ing that SOCS1-siRNA DNA preferentially enhances Th1-
polarized anti-HIV immune responses induced by DNA
vaccines. HIV Env-speciﬁc CTL responses were signiﬁcantly
enhanced by co-injection of pSuper-SOCS1-siRNA DNA, as
demonstrated by ELISPOT assays (Figure 8). Intracellular
IFN-c staining also showed enhanced gp120-speciﬁc CD8
þ T
cell responses in mice coimmunized with pSuper-SOCS1
siRNA DNA (Figure 8). Moreover, HIV Env-speciﬁc CD4
þ Th
responses were enhanced by co-injection of SOCS1-siRNA
DNA (Figure 8). These results indicate that pSuper-SOCS1
siRNA DNA coimmunization enhances the potency of HIV
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(A) Enhanced production of BAFF and APRIL by SOCS1-silenced DCs. The transduced BM-DCs were stimulated with LPS (100 ng/ml) for 24 h. Relative
expression levels of BAFF and APRIL mRNA were then determined by real-time quantitative PCR as described in Methods, and normalized to mock-
transfected DCs after LPS stimulation using the Comparative Ct method [27]. Representative data from two independent experiments are presented. *P
, 0.01, LV-SOCS1-siRNA-DC versus LV-GFP-siRNA-DCs.
(B–D) Enhanced activation of gp120-specific B cells by SOCS1-silenced DCs. Frequencies of anti-gp120 antibody-producing cells in different groupso f
mice were determined and reported as the number of cells secreting gp120-specific IgG per 5310
5 B cells (B). The proliferation rates (C) and cytokine
production (D) of B cells (5310
4/well) isolated from the spleens of different groups of mice after stimulation with anti-CD40 (5 lg/ml), IL-4 (20 ng/ml),
or costimulation with anti-CD40 and IL-4 for 48 h were determined, and results from one of three independent experiments are presented. P , 0.01, LV-
SOCS1-siRNA-DC mice versus LV-GFP-siRNA-DC mice under various in vitro stimulation conditions.
DOI: 10.1371/journal.pmed.0030011.g004
PLoS Medicine | www.plosmedicine.org January 2006 | Volume 3 | Issue 1 | e11 0085
HIV Vaccine/Immune Inhibitor SilencingDNA vaccination, probably due to the enhanced immuno-
stimulatory capacity of the cotransfected APCs in the
immunized mice. Thus, our SOCS1 silencing strategy is
applicable to ex vivo DC-based and in vivo vaccination
settings.
Discussion
In this study we found that silencing of the negative
signaling regulator SOCS1 in DCs results in drastic enhance-
ment of both HIV Env-speciﬁc CTL and antibody responses
in mice. We demonstrated that SOCS1-silenced DCs have an
enhanced ability to generate memory HIV Env-speciﬁc T cell
and B cell responses. We also found that SOCS1-restricted,
autocrine signaling of proinﬂammatory cytokines, such as IL-
12 in DCs, as well as production of proinﬂammatory
cytokines by DCs, play a critical role in inducing anti-HIV
immune response. In addition, we demonstrated that
coimmunization with SOCS1 siRNA DNA signiﬁcantly en-
hances the potency of HIV DNA vaccination. Thus, a
balanced memory humoral and cellular response against
HIV can be induced by SOCS1-silenced DCs and SOCS1-
siRNA DNA. This study indicates that SOCS1 functions as a
critical antigen presentation attenuator. Furthermore, this
SOCS1 silencing strategy is broadly applicable to enhancing
both therapeutic and prophylactic vaccines against HIV and
other pathogens.
The role of DCs in the induction of humoral responses has
been traditionally viewed as a consequence of CD4
þ Th
priming for cognate interaction between T cells and B cells.
However, the direct role of DCs in stimulation of the humoral
response has been documented in vitro and in vivo [42,47].
Notably, DCs were found to strongly enhance both prolifer-
ation and antibody production of CD40-activated B cells [42].
Immunization with DCs loaded with antigens can induce a
protective humoral response [48]. Here, we found that
SOCS1-silenced DCs enhance the production of Th2-polar-
izing cyokines as well as B lymphocyte stimulatory cytokines
(BAFF and APRIL), which is likely responsible for the
enhanced Th and B cell activation seen in SOCS1-silenced
DC-immunized mice. Our ﬁnding is supported by a previous
report that SOCS1
 /  DCs induce aberrant expansion of B
cells and autoreactive antibody production [20]. Hence, this
study demonstrates the critical role of SOCS1 in DCs in
controlling HIV-speciﬁc antibody responses and implies that
the silencing of SOCS1 can be generically used to boost
antibody responses against antigens other than HIV Env.
An important ﬁnding of this study is that SOCS1-silenced
DCs induce balanced, memory HIV Env-speciﬁc antibody and
CTL responses, which may be desirable for preventing or
controlling HIV infection [5,8–11,49,50]. Although the mech-
anism(s) by which SOCS1 silencing induces a balanced,
memory humoral and cellular response is unclear, it may
involve the enhanced production of a mixed pattern of Th1-
and Th2-polarizing cytokines by SOCS1-silenced DCs. These
results are consistent with mixed antibody and CTL responses
naturally generated against many pathogens such as viruses
[30], indicating that Th1 and Th2 polarization is not mutually
exclusive [32,51]. Hanada et al. recently found that the
expression of Eomes, a transcription factor, was selectively
overexpressed in SOCS1
 /  BM-DCs, which may be respon-
sible for the enhanced production of IFN-c [25]. Baetz et al.
[22] and Gingras et al. [23] recently reported that SOCS1
indirectly regulates TLR signaling in macrophages by
inhibiting the signaling of type I IFN that is induced by
TLR signaling. However, the Gingras et al. studies [15,22,23]
showed that levels of IL-12 produced by SOCS1
 /  BM-
derived macrophages were comparable to those by WT BM-
derived macrophages in response to LPS. We found that
SOCS1-silenced BM-DCs produced higher levels of proin-
ﬂammatory cytokines including IL-12 (p70 heterodimer) than
did LV-GFP-siRNA-DCs (see Figure 2B). Our results are also
consistent with two recent reports that SOCS1 KO macro-
phages produced excessive amounts of IL-12 and other
cytokines in response to stimuli, and that enhanced levels
of IL-12 and other cytokines were found in sera of condi-
tional SOCS1 KO mice [52,53]. We noticed that transduction
with control GFP-siRNA also enhanced the immunostimula-
tory potency of DCs, because siRNA molecules can stimulate
DCs via the activation of TLR signaling [54,55] and the direct
activation of some cellular genes such as the IFN-stimulated
genes [56]. Thus, the enhanced immunostimulatory potency
of DCs by SOCS1-siRNA is likely a collective result of SOCS1
silencing and nonspeciﬁc stimulatory effect of siRNA
molecules. The nonspeciﬁc stimulatory ability of siRNA
molecules may be an added beneﬁt of using siRNA to silence
a signaling inhibitor to enhance anti-HIV immunity.
The results of this study underscore the importance of
autocrine SOCS1-restricted signaling of proinﬂammatory
cytokines such as IL-12 in DCs for the induction of anti-
HIV immune responses. Proinﬂammatory cytokines have
been used to enhance the potency of HIV vaccines [57,58].
Here we found that in vivo stimulation with IL-12 or
cotransfection of recombinant Ad-IL-12 viruses only mod-
estly enhance anti-HIV immune responses induced by WT DC
immunization. In contrast, the anti-HIV immune responses
induced by SOCS1-silenced DC immunization were signiﬁ-
cantly enhanced by in vivo stimulation with IL-12 or
cotransfection of Ad-IL-12. These results indicate that the
signaling of proinﬂammatory cytokines and their stimulatory
effects on APCs are tightly restricted by SOCS1, which may
reﬂect the modest or no enhancement of the potency of HIV
vaccines by coexpression of various proinﬂammatory cyto-
kines [59]. The importance of autocrine signaling of proin-
ﬂammatory cytokines in antigen presentation was reported in
several recent studies [60,61]. In addition, we found that
SOCS1-silenced DCs have a superior ability to generate HIV-
speciﬁc memory T cell and B cell responses. The increase of
memory T cell and antibody responses was more profound
than that of primary responses induced by SOCS1-silenced
Figure 5. Long-Term gp120-Specific Antibody and CTL Responses Induced by SOCS1-Silenced DCs
IgG subclass titers (A) from pooled sera of different groups of mice and frequencies of IFN-c-positive T cells of CD8
þ T cells (B) and CD4
þ T cells (D)
isolated from pooled splenocytes (two mice per group) were determined at 6 mo after DC immunization and on day 7 after booster immunization with
recombinant gp120 emulsified in IFA (20 lg protein/mouse). Intracellular IFN-c and surface CD44 costaining of gated CD8
þT cells from splenocytes at 6
mo after immunization are shown (C). The data are representative of two experiments.
DOI: 10.1371/journal.pmed.0030011.g005
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generation are still poorly deﬁned, the fate of activated T
lymphocytes is likely determined by the strength under which
an antigen is presented by APCs [62–66]. The results of our
study suggest that unrestricted autocrine signaling, as well as
enhanced production of both Th1- and Th2-promoting
cytokines by SOCS1-silenced DCs, may account for the
enhanced ability of SOCS1-silenced DCs to induce memory
HIV-speciﬁc CTL and antibody responses. It is tempting to
postulate that enhanced expression and signaling of cyto-
kines such as IL-7 and IL-15 and other surface molecules,
which are involved in the generation of memory response
[67–69], by SOCS1-silenced DCs may be responsible for the
enhanced memory responses. Our results also suggest that the
quality of gp120-speciﬁc T cells, in addition to their
frequencies, may be enhanced by SOCS1-silenced DCs
(Figure S6). It would be interesting to systematically examine
the expression of granzyme, perforin, Fas ligand, and other
molecules on these antigen-speciﬁc T cells induced by
SOCS1-silenced DCs in a future study.
Functional defects and depletion of DCs are common in
HIV-infected individuals, likely contributing to the progres-
sive immunodeﬁciency. Peripheral mononuclear cells from
HIV-1-infected patients have been shown to produce
signiﬁcantly less IL-12 than those from uninfected controls
[70]. HIV gp120 protein can suppress the ability of DCs to
produce proinﬂammatory cytokines and to stimulate T cells
[37,71], although the mechanism by which gp120 suppresses
the production of proinﬂammatory cytokines is largely
uncharacterized. We found that SOCS1-silenced DCs are
more resistant to HIV gp120-mediated suppression, since
SOCS1-silenced DCs in the presence of gp120 proteins still
produced higher levels of IL-12 in response to LPS and
induced stronger CTL and antibody responses (see Figure 6).
This ﬁnding is especially relevant to the development of
therapeutic HIV vaccines, which would be used in immuno-
suppressed HIV-infected individuals [72]. The enhanced
resistance to gp120-mediated suppression may be due to
the unbridled proinﬂammatory STAT (1/2/4) signaling in
SOCS1-silenced DCs to antagonize anti-inﬂammatory signal-
ing mediated by HIV gp120. In this study we treated DCs with
high concentrations of soluble recombinant HIV gp120
proteins largely in a monomeric form, which may not reﬂect
the physiologic conditions of HIV infection. Further studies
are needed to investigate precise molecular mechanisms
responsible for the enhanced resistance of SOCS1-silenced
DCs to HIV suppression in a condition closely resembling
natural HIV infection.
The vaccination strategy described here, to our knowledge,
represents the ﬁrst effort to enhance anti-HIV immune
responses by inhibiting the host’s immune inhibitors in DCs.
Since natural immunity is ineffective in controlling HIV-1
Figure 6. Resistance of SOCS1-Silenced DCs to HIV gp120-Mediated Suppression
(A) Effects of gp120 on cytokine production by DCs. BM-DCs were transfected with SOCS1-siRNA or a SOCS1-siRNA mutant oligonucleotide as described
previously [24], and then cultured with or without SF162 gp120 (20 lg/ml) or LPS (100 ng/ml), and cytokine levels were determined at the different
times of cultures, as indicated.
(B–E) Effects of gp120 on DC antigen presentation in vivo. Transfected BM-DCs were pulsed with OVA, incubated with or without gp120 for 2 d, and
then stimulated with LPS (100 ng/ml) ex vivo overnight. Mice were then immunized with the transduced DCs twice, following three in vivo LPS
stimulations. OVA-specific antibody IgG (B) and IgG1 (C) titers and frequencies of IFN-c-producing OVA-specific CD8
þ T cells (D) and CD4
þ T cells (E)
were examined 2 wk after the second DC immunization. Data are representative of two repeats.
DOI: 10.1371/journal.pmed.0030011.g006
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critical to generate effective anti-HIV immune responses.
However, mere enhancement of HIV-speciﬁc immune re-
sponses may not lead to the induction of protective HIV
antibodies and CTL responses. In this regard, our approach
offers the opportunity for combinational immunization with
currently available vaccines, as demonstrated by our coim-
munization of DNA vaccine and SOCS1 siRNA DNA. When
used with improved HIV immunogens and delivery systems
[5,73], this vaccination approach may provide a new avenue
to enhance weak protective immune responses or generate
broader and stronger responses not only against dominant
epitopes, but also against weakly immunogenic or cryptic, yet
protective epitopes.
Current efforts in HIV immunotherapy and vaccine
development are largely aimed at stimulating anti-HIV
immune responses by modifying HIV antigens and using
various delivery systems and adjuvants. This study demon-
strates the principle of disabling a signaling inhibitor in host
DCs as an alternative and effective HIV immunization
approach, which could be translated into the clinic. Indeed,
our recent study identiﬁed a human SOCS1 siRNA and
demonstrated that human SOCS1-silenced DCs also had
enhanced immunostimulatory capacity to activate antigen-
speciﬁc CTL responses (unpublished data). The SOCS1 siRNA
molecule or expression cassette can be incorporated into
various forms of prophylactic HIV vaccines, including DNA-,
adenovirus-, vaccinia-, poxvirus-, virus-like particle-, and
other vector-based vaccines. Furthermore, immunization of
HIV-infected patients with DCs loaded with inactivated HIV
viruses led to a reduction in viral loads and an increase in
CD4
þT cell numbers in the blood [72], suggesting that SOCS1
silencing could augment the effect of therapeutic HIV
vaccines for the long-term control of HIV infection. Thus,
further investigations are warranted to determine if protec-
tive anti-HIV responses would be induced by this SOCS1
silencing strategy in monkeys and ultimately in humans.
Supporting Information
Figure S1. Enhanced gp120-Speciﬁc Antibody and CTL Responses
Induced by SOCS1-Silenced DCs
Groups of C57BL/6 mice were immunized with gp120 (SF162) protein-
pulsed, transduced BM-derived DCs (1 3 10
6 cells/mouse) twice at a
weekly interval without in vivo LPS stimulation, and sera and
splenocytes were collected from each group of mice 14 d later. HIV
gp120-speciﬁc IgG (A) and subclass (B) titers from the pooled sera of
each group (4–6 mice/group) were quantiﬁed by capture ELISA.
Antibody titers are reported as the mean 6 standard deviation of
endpoint titers [24]. Pooled splenocytes from the immunized mice
were subjected to CTL assays against gp120 protein-pulsed syngeneic
Figure 7. The Role of IL-12 Signaling in Enhanced Anti-HIV Immunity
(A and B) In vivo injection with IL-12 preferentially enhanced gp120-specific CTL and Th responses induced by SOCS1-silenced DCs. C57BL/6 mice were
immunized with 1 3 10
6 of HIV gp120-pulsed (50 lg/ml), transduced DCs derived from BM of WT mice or IL-12 receptor KO mice with ex vivo TNFa
maturation (50 ng/ml). On days 1, 3, and 5 after DC immunization, murine IL-12 (1 lg/mouse, Peprotech) was administered intraperitoneally. CD8
þ T
cells (A) or CD4
þT cells (B) isolated 2 wk later from the pooled splenocytes of immunized mice (2–3 each group) were subjected to IFN-c ELISPOT assays.
An irrelevant protein, OVA, was used as a negative control. Representative data from two independent experiments are presented. *P , 0.01, LV-SOCS1-
siRNA-DC versus LV-SOCS1-siRNA-DC þ IL-12, or IL12R KO LV-SOCS1-siRNA-DC þ IL-12 versus LV-SOCS1-siRNA-DC þ IL-12.
(C and D) gp120-specific CTL and Th responses induced by SOCS1-silenced DCs or Ad-IL-12-DCs. BM-derived DCs from WT mice were transfected with
LV-SOCS1-siRNA (MOI of 5) or Ad-IL-12 with various MOIs of 10–1,000 or cotransfected with LV-SOCS1-siRNA (MOI of 5) and Ad-IL-12 (MOI of 10) for 4 h.
DCs derived from BM of IL-12 receptor KO mice were cotransfected with LV-SOCS1-siRNA (MOI of 5) and Ad-IL-12 (MOI of 10) for 4 h. Groups of C57BL/6
mice were immunized with 1 3 10
6 of gp120-pulsed (50 lg/ml), transfected DCs with ex vivo TNFa maturation. CD8
þ T-cells (C) or CD4
þ T cells (D)
isolated 2 wk later from the pooled splenocytes of immunized mice (2–3 each group) were subjected to IFN-c ELISPOT assays. An irrelevant protein,
OVA, was used as a negative control. Representative data from two independent experiments are presented. P , 0.01, Ad-IL-12/SOCS1-siRNA-DC versus
IL-12-DCs, or Ad-IL-12/SOCS1-siRNA-DC versus IL12R KO Ad-IL-12/SOCS1-siRNA-DC.
DOI: 10.1371/journal.pmed.0030011.g007
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HIV Vaccine/Immune Inhibitor SilencingTC-1 cells (C). Representative data from one of three experiments are
presented. *P , 0.01, LV-SOCS1-siRNA-DCs versus LV-GFP-siRNA-
DCs.
Found at DOI: 10.1371/journal.pmed.0030011.sg001 (74 KB PDF).
Figure S2. gp120-Speciﬁc Antibody and CTL Responses Enhanced by
SOCS1-Silenced DCs and In Vivo LPS Stimulation
Groups of C57BL/6 mice were immunized with gp120 (SF162) protein-
pulsed, transduced BM-derived DCs (1 3 10
6 cells/mouse) twice at a
weekly interval, followed by LPS stimulation (30 lg/mouse) in vivo
three times on days 1, 3, and 5 after each DC immunization, and sera
and splenocytes were collected from each group of mice 14 d later.
HIV gp120-speciﬁc IgM and IgG (A) and IgG subclass (B) titers from
the pooled sera of each group (4–6 mice/group) were quantiﬁed by
capture ELISA. Pooled splenocytes from the immunized mice were
subjected to CTL assays against gp120 protein-pulsed syngeneic TC-1
cells (C). CD8
þT cells isolated from the splenocytes were used for IFN-
c ELISPOT assays stimulated with gp120 proteins or control BSA (D).
Representative data from one of three experiments are presented. *P
, 0.01, LV-SOCS1-siRNA-DCs versus LV-GFP-siRNA-DCs.
Found at DOI: 10.1371/journal.pmed.0030011.sg002 (72 KB PDF).
Figure S3. Enhanced NK Activities in Mice Immunized with SOCS1-
Silenced DCs
Splenocytes pooled from each group of mice immunized with gp120-
pulsed BM-DCs (1 3 10
6 cells/mouse) were examined for NK activity
using a 5-h
51Cr release assay against Yac-1 cells. Data are
representative of three independent experiments. P , 0.05, LV-
SOCS1-siRNA-DCs versus LV-GFP-siRNA-DCs.
Found at DOI: 10.1371/journal.pmed.0030011.sg003 (50 KB PDF).
Figure S4. Comparison of T Cell Responses Boosted by Various TLR
Agonists
Groups of C57BL/6 mice were immunized with gp120 protein-pulsed,
LV-SOCS1-siRNA-transduced DCs (1 3 10
6 cells/mouse) twice at a
weekly interval, followed by in vivo stimulation with LPS, PolyI:C, or
R837 (30 lg/mouse) three times on days 1, 3, and 5 after each DC
immunization. CD8
þ T cells isolated from the splenocytes were used
for IFN-c ELISPOT assays stimulated with gp120 proteins 14 d later.
NS, no in vivo stimulation with any TLR agonist. *P , 0.01, NS versus
LPS, PolyI:C, or R837.
Found at DOI: 10.1371/journal.pmed.0030011.sg004 (48 KB PDF).
Figure S5. E n h a n c e dP e r f o r i nE x p r e s s i o ni nTC e l l so fM i c e
Immunized with SOCS1-Silenced DCs
Groups of C57BL/6 mice were immunized with gp120-pulsed,
transduced BM-derived DCs (1 3 10
6 cells/mouse) or the same
amount of gp120 protein formulated in IFA (20 lg/mouse) twice at a
weekly interval. All of the mice were injected with PolyI:C (30 lg/
mouse) in vivo three times on days 1, 3, and 5 after each
immunization, and splenocytes were collected from each group of
mice 14 d later. The splenocytes were in vitro restimulated with
gp120 protein-pulsed BM-DCs for 5 h and then costained with anti-
CD8-FITC and anti-Perforin-PE (BD Pharmingen) for FACS analysis.
Found at DOI: 10.1371/journal.pmed.0030011.sg005 (66 KB PDF).
Figure S6. Enhanced Expression of Eomes in LV-SOCS1-siRNA-
Transduced DCs
The expression of Eomes and T-bet in the transduced DCs after 24 h
of LPS stimulation was examined by RT-PCR, as described by Hanada
et al. [25]. GAPDH was used as an internal control. A pair of primers
used for T-bet ampliﬁcation were 59-CCCACAAGCCATTACAGG-39
and 59-AGTGATCTCTGCGTTCTGGT-39; a pair of primers for
Eomes ampliﬁcation was 59-TGAATGAACCTTCCAAGACTCAGA-39
and 59-GGCTTGAGGCAAAGTGTTGACA-39; and a pair of primers
for GAPDH ampliﬁcation was 59-ACCACAGTCCATGCCATCAC-39
and 59-TCCACCACCCTGTTGCTGTA-39.
Found at DOI: 10.1371/journal.pmed.0030011.sg006 (75 KB PDF).
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Background. When you are vaccinated against a virus, you are given a
harmless form of the virus. A particular part of the virus—a part called an
‘‘antigen’’—triggers your immune system to produce a response that
includes antibodies (proteins secreted into the blood that bind just to
that antigen) and specific cells. If one day you are infected with the
actual virus, your body now has the means to fight it off. Despite a great
deal of work going into the development of a vaccine against HIV, so far
no vaccine has been produced. There are a number of possible reasons
for this lack of success. For example, it has not been easy to identify the
ideal part on the virus (the ideal antigen) that would trigger the immune
system to produce a response. Also, we have not yet found a way to
trigger a strong enough immune response against any experimental HIV
vaccine. One group of cells involved in producing an immune response is
known as antigen-presenting cells. These cells are responsible for
handling antigens from viruses (and other microbes, such as bacteria) so
that the body’s immune system can respond efficiently and eliminate the
microbe. The activity of these cells is controlled by molecular signals
(cytokines) inside the cell.
Why Was This Study Done? The authors wanted to take a different
approach from the one described above to producing a vaccine. Our
immune systems are kept in check by molecules called ‘‘immune
inhibitors.’’ These prevent our immune systems from attacking our own
bodies. These inhibitors might also be preventing our own immune
systems from mounting an effective immune response to an HIV vaccine.
The authors thought that by ‘‘switching off’’ or silencing these inhibitors,
this might help the immune system to trigger a response against an HIV
vaccine. They tested their hypothesis in a laboratory study of mice. They
switched off a particular immune inhibitor called ‘‘SOCS1’’ inside a type
of antigen-presenting cell called a dendritic cell, and looked at whether
this would boost the mouse immune response in general, and whether it
would lead to a more effective immune response against an HIV vaccine.
What Did the Researchers Do and Find? They found that silencing
SOCS1 in dendritic cells increased the immune response, and that this
response was long-lasting. They also showed that when this strategy was
combined with vaccination using genetic material (DNA) from HIV, the
vaccine was more effective.
What Do These Findings Mean? It seems that it may be possible to
boost the body’s response to HIV vaccination by switching off an
immune inhibitor. However, these results are preliminary, as this
approach has at the moment not been tested in humans, and before
it is clear whether it will work in humans much research will need to be
done, including assessing whether the approach is safe.
Where Can I Get More Information Online? Medline Plus has many
links to pages of information on HIV:
http://www.nlm.nih.gov/medlineplus/aids.html
The Body has a page of links on the search for an HIV vaccine:
http://www.thebody.com/treat/vaccines.html
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